The use of finasteride 3 demonstrated a sustained improvement in the treatment of androgen dependent diseases and reduction in prostate specific antigen (PSA) levels. 5) Related analogs 4, 5 and 6 ( Fig. 1 ) have also demonstrated effectiveness in vitro and in vivo. 6, 7) Androstane-3-carboxylic acids 7 and 8 ( Fig. 1) were recently synthesized and have shown a potent uncompetitive inhibition of type 2 5-a reductase. 8, 9) Epristeride 7 has exhibited the ability to lower serum DHT 2 levels by 50%. 10) In this study we evaluated the following compounds as antiandrogens: 17-a acetoxyprogesterone 9 ( Fig. 2 ), 17-a acetoxy-4, 5-epoxypregnan-3, 20-dione 10, 17-a acetoxy-4-chloro-4-pregnene-3, 20-dione 11, 17-a acetoxy-4-bromo-4-pregnene-3, 20-dione 12, 17-a hydroxy-4-bromo-4-pregnene-3, 20-dione 13, 4-chloro-17-a hydroxy-4-pregnene-3, 20-dione 14, 17-a benzoyloxy-4-bromo-4-pregnene-3, 20-dione 15 and 17-a benzoyloxy-4-chloro-4-pregnene-3, 20-dione 16.
The biological activity of these steroids was determined on in vitro metabolic change in the T (1) molecule produced by 5-a reductase 11, 12) and by the in vivo steroid action upon the seminal vesicles, 12) where the compound is bound to its cognate receptors. 12, 13) To test the antiandrogenic effect of the synthesized compounds, we used the seminal vesicles of gonadectomized male hamsters. 11, 12) Seminal vesicles are male accessory glands that are androgen dependent. These organs are capable of reducing T (1) to DHT (2) in both intact and gonadectomized animals. 14) Chemistry As shown in Fig. 2 the active compounds 11, 12, 15 and 16 were synthesized from the commercially available 17-a acetoxyprogesterone 9. Previous reports indicated that compound 9 was synthesized by Mukawa in Japan. 15) In the first step, the C-4 double bond of 9 was epoxydized with hydrogen peroxide in basic medium 16, 17) ; the desired compound 10 underwent a ring opening reaction with hydrogen chloride or hydrogen bromide to form the corresponding chloroderivative 18) 11 and the bromo compound 18) 12. Treatment of 11 and 12 with aqueous sodium hydroxide solution 19) afforded the corresponding alcohols 13 and 14. The esterification of the C-17 hydroxyl group in 13 and 14 with benzoic acid and trifluoroacetic anhydride 19) afforded the desired final compounds 15 (4-bromo derivative) and 16 (4-chloro derivative).
Methods and Results
Seminal Vesicles When 1 (T) and finasteride 3 were injected together, the weight of the seminal vesicles decreased significantly ( pϽ0.005) as compared to T (1) treated animals ( Table 1 ). The starting material 9 and the intermediate epoxy compound 10 failed to show a substantial decrease of the weight of the seminal vesicles (lack of an antiandrogenic effect). Steroids 11-16 decreased the weight of the glands significantly ( pϽ0.005) as compared to the T (1) treated animals. Table 1 shows that compound 16 (17-a benzoyloxy-4-chloroderivative) has the highest antiandrogenic effect; the corresponding 4-bromoderivative 15 is slightly less active. On the other hand, compound 12 (17-a acetoxy-4-bromoderivative) is more active than the corresponding chloroderivative 11. Surprisingly the benzoyloxyderivatives 15 and 16 have a much higher antiandrogenic activity than the corresponding acetoxy compounds, 11 and 12. The starting material 9, showed a very weak antiandrogenic effect, whereas the alcohols 13 and 14, the epoxyderivative 10 did not show a comparable pharmacological activity.
Since the weight of the seminal vesicles depends on the 5-a reduced androgens, 1, 20) it was important to determine the effect of these compounds on the conversion of T (1) to DHT (2) in this tissue.
The hexane extract from castrated male hamster seminal vesicles was subjected to TLC analysis. The zone corresponding to the DHT (2) standard (Rf value 0.33) of each experimental chromatogram was eluted and the radioactivity determined.
The results (Fig. 3 ) obtained from two separate experiments performed in duplicate demonstrated a difference between the conversion of [ 3 H]T to [ 3 H]DHT in the T plus finasteride 3-treated animals thus indicating that finasteride 3 is a good inhibitor for the conversion of T to DHT at pH 6. The radioactive purity of the formed DHT is shown in Table 2. Figure 3 shows the effect of steroidal structure on the rate of DHT formation expressed as pmoles of DHT/g of protein/h. The most active compounds 11, 12 and 16 show a lower rate of DHT formation than the control samples, T and T plus finasteride 3 (Tϩ3). The 4-bromo-17-a benzoyloxy compound 15 although showed relatively high antiandrogenic activity (Table 1) in this case, it did not reduce the rate of DHT formation and showed a weak activity as T conversion inhibitor.
Discussion
This paper describes the synthesis of 6 steroidal compounds 11-16 (Fig. 2) . The starting material 9 and the intermediate 10 are devoid of a halogen atom at C-4 and are biologically inactive. Steroids 12, 14 and 16 have a chlorine atom at C-4 whereas 11, 13 and 15 contain a bromine atom at the same position. Compounds 11, 12 and 14 are known and were previously prepared by Japanese workers. 21, 22) All of the bromo and chloro derivatives are biologically active as T conversion inhibitors and also show a significant decrease of the weight of seminal vesicles (Table 1 ) and therefore could be considered as antiandrogens. Figure 3 shows the conversion of [ 3 H]T to [ 3 H]DHT expressed as pmoles of DHT/g of protein/h. Finasteride (3) reduces the conversion of T to DHT substantially and therefore can be considered as a 5-a reductase inhibitor at pH 6. Other authors who reported the inhibitory effect of similar compounds in agreement with those obtain these results. 23, 24) Steroids 11, 12, and 16 inhibited significantly ( pϽ0.005) the conversion of T to DHT at pH 6 in seminal vesicles homogenates from castrated male hamsters treated with a dose of 200 mg as compared to T (1).
This antiandrogenic effect of 11-16 is probably due to the presence of a halogen substituent at C-4 on the progesterone molecule (Fig. 2) . Similar compounds with a halogen atom at C-6 have shown a very high antiandrogenic activity. 11, 12, 25) The results in Table 1 clearly indicate that compounds 15 and 16 with the benzoyloxy moiety at C-17 show a much higher antiandrogenic effect as compared to 11 and 12 with an acetoxy group at C-17. In the benzoyloxy series, compound 16 (chlorine at C-4) shows a higher antiandrogenic effect than the analog bromo derivative 15. In the 17-a-acetoxy series, this behavior is reversed; the chloro derivative 11 shows a lower antiandrogenic activity than the corresponding bromo compound 12.
The data for protein synthesis (Table 1) indicate that when a significant decrease ( pϽ0.005) in the weight of the seminal vesicles has taken place, protein formation is increased. On the other hand, when the T conversion is inhibited, protein synthesis is increased (lower DHT formation) ( Table 1) . These proteins could be enzymes, membrane proteins, or cytosol receptors. These data are in agreement with those previously published by our group 12) and by Takayasu and Itami 26) who demonstrated that the synthesis of 5-a reductase enzyme is induced by androgen deprivation in hamster sebaceous glands. 20) Probably in the future, compounds 11, 12, and 16 could have a potential application for the treatment of androgen dependent diseases.
Experimental
Chemicals and Radioactive Material Solvents were laboratory grade or better. Melting points were determined on a Fisher Johns melting point apparatus and are uncorrected. 2.14 (3H, s), 3.01 (1H, s). 
17-a a Acetoxy-4-chloro-4-pregnene-3, 20-dione (11)
To a solution of 10 (1 g, 2.6 mmol) in acetone (50 ml) was added concentrated hydrochloric acid (1 ml). The solution was allowed to reflux for 30 min. The organic solvent was evaporated in vacuum and the desired crude product 11 was precipitated upon addition of 200 g of ice. Yield 0.99 g, 2.4 mmol (92%). Recrystallization from methanol afforded the pure product 0.78 g (78% 17-a a Acetoxy-4-bromo-4-pregnene-3, 20-dione (12) To a solution of 10 (1 g, 2.6 mmol) in methanol (30 ml) was added concentrated hydrobromic acid (15 ml). The mixture was stirred for 12 h at room temperature, water (100 ml) was added and upon cooling the desired crude compounds 12 precipitated 0.98 g. The crude product was recrystallized from methanol to give 0.70 g, 
17-a a Hydroxy-4-bromo-4-pregnene-3,20-dione (13)
To a solution of 12 (1 g, 2.6 mmol) in methanol (100 ml) was added a 2% solution of sodium hydroxide (25 ml) and the mixture was allowed reflux for 30 min. The methanol was evaporated in vacuum and to the aqueous phase it was added water (20 ml). The mixture was extracted 3 times with chloroform and the combined organic phases were washed repeatedly with water until a pH of 7. The chloroform solution was dried with sodium sulfate and the organic solvent was -vaporated in vacuum. The crude product was purified by column chromatography (hexane : AcOEtϭ6 : 4) and recrystallized from methanol to give 0.71 g, 
4-Chloro-17-a a hydroxy-4-pregnene-3, 20-dione (14)
To a solution of 11 (1 g, 1.2 mmol) in methanol (30 ml) was added a 2% solution of sodium hydroxide (50 ml) and the mixture was allowed to reflux to for 30 min. The methanol was evaporated in vacuum and to the aqueous phase was added water (30 ml). It was extracted 3 times with chloroform and the combined organic phases were washed repeatedly with water to a pH of 7. The chloroform solution was dried with sodium sulfate and the organic solvent was evaporated in vacuum. The crude product was purified by column chromatography (hexane : AcOEtϭ6 : 4) and recrystallized from methanol to give 0.68 g. Benzoyloxy-4-bromo-4-pregnene-3, 20-dione (15) To a solution of 13 (50 mg, 1.2 mmol) in chloroform (5 ml) was added benzoic acid 0.6 g, 4.9 mmol, PTSA acid (10 mg, 5.7 mmol) and trifluoroacetic anhydride (0.2 ml, 2.7 mmol). The resulting solution was stirred under nitrogen for 17 h at room temperature. Ice water was added and the reaction mixture was neutralized with sodium bicarbonate to a pH of 7. The solution was extracted with chloroform; the combined organic extracts were washed with water, dried over sodium sulfate and the solvent evaporated in vacuum. The crude product was purified by column chromatography (hexane : AcOEtϭ7 : 3) to give 30 mg, 0.6 mmol (50%) of the pure compound 15. mp 225-228°C. UV: 253 nm (log e, 4.12). IR (KBr): 1669, 1702, 1718. 17-a a Benzoyloxy-4-chloro-4-pregnene-3, 20-dione (16) To a solution of 14 (50 mg, 1.4 mmol) in chloroform (5 ml) was added benzoic acid (0.6 g, 4.9 mmol), PTSA acid (10 mg, 5.7 mmol) and trifluoroacetic anhydride (0.2 ml, 2.7 mmol). The resulting solution was stirred under nitrogen for 17 h at room temperature. Ice water was added and the reaction mixture was neutralized with sodium bicarbonate to a pH of 7. The solution was extracted with chloroform; the combined organic extracts were washed with water, dried over sodium sulfate and the solvent evaporated in vacuum. Two separate experiments were performed for each group of steroidtreated animals. The results were analyzed using one-way analysis of variance with EPISTAT software.
17-a a
In Vitro Metabolic Studies with Seminal Vesicles Homogenates from male hamster seminal vesicles (around 3 mg protein) were prepared from intact adult male animals, using Krebs-Ringer-phosphate buffer solution, at pH 6. Tissue preparations were incubated 12) in duplicate with 5.1 mM [ 3 H]T in the presence of 1 mM NADPH ϩ , 0.013 mM of unlabeled T, finasteride 3, compounds 11-16 in a Dubnoff metabolic incubator at 37°C for 60 min with O 2 /CO 2 (95/5) as the gas phase. The final incubation volume was 1 ml. Incubations without tissues were used as controls. Incubation was terminated by addition of dichloromethane, and the [ 3 H]steroid was extracted (4ϫ) using 3 vol of dichloromethane. The solvent was dried under vacuum and the extract washed with hexane in order to remove the remaining lipids. The protein content of the homogenates was determined by Bradford's dyebinding method 4) using bovine serum albumin (BSA) as the standard. Isolation and purity assessment of radioactive DHT was carried out by the reverse isotope dilution technique. The isolated compound was purified with steroid carriers (T, DHT) in a thin-layer chromatographic system (chloroform-acetone, 9 : 1). The radioactive conversion product was identified on chromatographic plates by autoradiography, while nonradioactive steroid carriers were detected using phosphomolybdic acid reagent and an ultraviolet lamp (254 nm). Radioactivity was determined in a Packard 3255 liquid scintillation spectrometer, using Ultima Gold (Packard, Downers Grove, IL) as the counting solution. The counting efficiency of 3 H was 67%. The calculated loss of radioactivity during the procedure was in agreement with the results obtained from a control experiment without tissue. The formation of DHT was calculated and expressed as pmol of DHT/g protein/h.
The specific activity of the DHT formed was determined by double isotope dilution, adding radioinert DHT to the eluting fraction from the TLC. The specific activity was calculated in dpm/mg of crystals.
